Albert Luderer joins BioNano Genomics board
This article was originally published in Scrip
BioNano Genomics, a company using its nanoAnalyzer technology platform to gain a better understanding of genomes, has elected Dr Albert Luderer to its board of directors. Dr Luderer has over 30 years' experience in biotech, having previously served as president and CEO of BioTrove. He is currently CEO and director of Integrated Diagnostics.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.